Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208
Status: Enrolling
Updated:  1/22/2018
Orlando Clinical Research Center (OCRC)
mi
from
Orlando, FL
Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment
The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208
Status: Enrolling
Updated: 1/22/2018
Orlando Clinical Research Center (OCRC)
mi
from
Orlando, FL
Click here to add this to my saved trials
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals
mi
from
Valley Forge, PA
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals
mi
from
Valley Forge, PA
Click here to add this to my saved trials
Safety and Efficacy of Iron Sucrose in Children
Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceutials
mi
from
Norristown, PA
Safety and Efficacy of Iron Sucrose in Children
Comparison of the Safety and Efficacy of Three Iron Sucrose Maintenance Regimens in Pediatric Chronic Kidney Disease (CKD) Patients
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceutials
mi
from
Norristown, PA
Click here to add this to my saved trials
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Comparison of Safety & Efficacy of a Unique Intravenous Iron (VIT45) Preparation vs Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients With Iron Deficiency Anemia and Impaired Renal Function
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)
Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study
Status: Enrolling
Updated:  1/25/2018
University of Michigan School of Medicine
mi
from
Ann Arbor, MI
Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)
Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study
Status: Enrolling
Updated: 1/25/2018
University of Michigan School of Medicine
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)
Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study
Status: Enrolling
Updated:  1/25/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)
Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study
Status: Enrolling
Updated: 1/25/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
University of Colorado at Denver
mi
from
Denver, CO
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
University of Colorado at Denver
mi
from
Denver, CO
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
Tampa General Hospital
mi
from
Tampa, FL
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
University of Illinois Medical Center, Chicago
mi
from
Chicago, IL
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
University of Illinois Medical Center, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
The Christ Hospital
mi
from
Cincinnati, OH
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
The Christ Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
University of Cincinnati
mi
from
Cincinnati, OH
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
University of Wisconsin-Madison
mi
from
Madison, WI
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated:  1/30/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Belatacept Early Steroid Withdrawal Trial
Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation
Status: Enrolling
Updated: 1/30/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Vascular Changes Following Forearm Loop Arteriovenous Graft Placement
The Natural History of Upper Arm Vessels Following Forearm Loop Arteriovenous
Status: Enrolling
Updated:  2/1/2018
University of Nebraska Medical Center/The Nebraska Medical Center
mi
from
Omaha, NE
Vascular Changes Following Forearm Loop Arteriovenous Graft Placement
The Natural History of Upper Arm Vessels Following Forearm Loop Arteriovenous
Status: Enrolling
Updated: 2/1/2018
University of Nebraska Medical Center/The Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Arteriovenous Fistula Tissue Bank
Arteriovenous Fistula Tissue Bank
Status: Enrolling
Updated:  2/1/2018
University of Nebraska Medical Center/The Nebraska Medical Center
mi
from
Omaha, NE
Arteriovenous Fistula Tissue Bank
Arteriovenous Fistula Tissue Bank
Status: Enrolling
Updated: 2/1/2018
University of Nebraska Medical Center/The Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated:  2/6/2018
Division of Clinical Pharmacology, University of Miami
mi
from
Miami, FL
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated: 2/6/2018
Division of Clinical Pharmacology, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated:  2/6/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated: 2/6/2018
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated:  2/6/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated: 2/6/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated:  2/6/2018
Prism Clinical Research
mi
from
Saint Paul, MN
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated: 2/6/2018
Prism Clinical Research
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated:  2/6/2018
QPS Bio-Kinetic
mi
from
Springfield, MO
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
Status: Enrolling
Updated: 2/6/2018
QPS Bio-Kinetic
mi
from
Springfield, MO
Click here to add this to my saved trials
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated:  2/8/2018
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Status: Enrolling
Updated: 2/8/2018
University of Colorado at Denver and Health Sciences Center
mi
from
Denver, CO
Click here to add this to my saved trials
Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)
Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
Status: Enrolling
Updated:  2/8/2018
Baylor Heart and Vascular Institute
mi
from
Dallas, TX
Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)
Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)
Status: Enrolling
Updated: 2/8/2018
Baylor Heart and Vascular Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Chronic Kidney Disease Antidepressant Sertraline Trial
Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease
Status: Enrolling
Updated:  2/9/2018
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
mi
from
Dallas, TX
Chronic Kidney Disease Antidepressant Sertraline Trial
Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease
Status: Enrolling
Updated: 2/9/2018
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
mi
from
Dallas, TX
Click here to add this to my saved trials
Chronic Kidney Disease Antidepressant Sertraline Trial
Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease
Status: Enrolling
Updated:  2/9/2018
UT Southwestern Medical Center
mi
from
Dallas, TX
Chronic Kidney Disease Antidepressant Sertraline Trial
Randomized Trial of Sertraline Treatment of Depression in Chronic Kidney Disease
Status: Enrolling
Updated: 2/9/2018
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Status: Enrolling
Updated:  2/16/2018
Novartis Investigative Site
mi
from
Orlando, FL
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Status: Enrolling
Updated: 2/16/2018
Novartis Investigative Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Status: Enrolling
Updated:  2/16/2018
Novartis Investigative Site
mi
from
Bucuresti,
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
Status: Enrolling
Updated: 2/16/2018
Novartis Investigative Site
mi
from
Bucuresti,
Click here to add this to my saved trials
Communicating About Choices in Transplantation
Communicating About Choices in Transplantation (COACH)
Status: Enrolling
Updated:  2/19/2018
Virginia Commonwealth University
mi
from
Richmond, VA
Communicating About Choices in Transplantation
Communicating About Choices in Transplantation (COACH)
Status: Enrolling
Updated: 2/19/2018
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Stanford School of Medicine
mi
from
Palo Alto, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Stanford School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Balboa Institute of Transplantation
mi
from
San diego, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Balboa Institute of Transplantation
mi
from
San diego, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Sharp Memorial Hospital
mi
from
San Diego, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Yale-New Haven Hospital
mi
from
New Haven, CT
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Yale-New Haven Hospital
mi
from
New Haven, CT
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
University of Florida
mi
from
Gainesville, FL
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Tampa General Hospital
mi
from
Tampa, FL
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
NUCATS's Clinical Research Unit
mi
from
Chicago, IL
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
NUCATS's Clinical Research Unit
mi
from
Chicago, IL
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Henry Ford Hospital
mi
from
Detroit, MI
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Hurley Medical Center
mi
from
Flint, MI
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Investigational Drug Services (IDS) / UNC Healthcare
mi
from
Chapel Hill, NC
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Investigational Drug Services (IDS) / UNC Healthcare
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
University of North Carolina, Department of Medicine/Nephrology
mi
from
Chapel Hill, NC
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
University of North Carolina, Department of Medicine/Nephrology
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Hahnemann University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated:  2/20/2018
Medical University of South Carolina, Department of Transplantation Surgery
mi
from
Charleston, SC
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients
Status: Enrolling
Updated: 2/20/2018
Medical University of South Carolina, Department of Transplantation Surgery
mi
from
Charleston, SC
Click here to add this to my saved trials